Clinical and neurocognitive outcomes after transcatheter aortic valve implantation (TAVI) with cerebral protection: initial experience with a novel dual-filter device in Southeast Asia

Paul Toon Lim Chiam1,2, MMed, MRCP, Nien Shen Chan3, MBBS, MRCP, Yean Teng Lim2,4, MMed, MRCP, Choon Pin Lim4, MMed, MRCP, Dinesh Nair5, MBBS, MRCP, Tai Tian Lim6, MD, Chao Yang Soon7, MBChB, MRCP, Brian Chung Hoe Khoon8, MBBS, MRCP, Jimmy Lim9, MBBS, MRCP, Kok Soon Tan9, MBBS, MRCP, Leslie Lam10, MBChB, FRCP, Peter Yan11, MBBS, MRCP, Yau Wei Ooi12, MBBS, MRCP, Mei Sian Chong13,14, MMed, MRCP

INTRODUCTION Transcatheter aortic valve implantation (TAVI) is increasingly performed in patients with severe aortic stenosis. A novel dual-filter system to reduce cerebral embolism during TAVI recently became available. We aimed to assess the feasibility, safety, and clinical and neurocognitive outcomes of TAVI with cerebral protection in Asian patients.

METHODS 40 consecutive patients undergoing TAVI with cerebral protection were enrolled. All procedures were performed via femoral access using the self-expanding Evolut R/PRO or Portico, or the balloon-expandable SAPIEN 3 bioprostheses. Baseline characteristics, procedural and clinical outcomes were recorded. Cognition was assessed at baseline and 30 days using the abbreviated mental test (AMT).

RESULTS The mean age of the patients (75% male) was 76.4 ± 8.4 years. TAVI was uncomplicated in all patients. The filter device was successfully deployed in 38 (95.0%) patients without safety issues. There was no stroke or death at 30 days, and the survival rate at nine months was 95.0%. There was no overall cognitive change (baseline vs. 30-day AMT: 9.2 ± 1.1 vs. 9.0 ± 1.5, p = 0.12), and only 1 (2.5%) patient developed impaired cognition at 30 days. Patients with a decreased AMT score at 30 days were significantly older than those without (82.1 ± 4.5 vs. 74.4 ± 7.7 years, p = 0.019). All patients with decreased AMT scores were aged ≥ 76 years.

CONCLUSION In this early Asian experience of TAVI under cerebral protection, the filter device was successfully deployed in 95% of patients, with 100% procedural success. There were no filter-related complications and no stroke or mortality at 30 days. Overall cognition was preserved, although increased age was associated with a decline in AMT score.

Keywords: aortic valve stenosis, Asia, cognition, stroke, transcatheter aortic valve replacement

INTRODUCTION Percutaneous transcatheter aortic valve implantation (TAVI), also known as transcatheter aortic valve replacement, has become an established treatment for patients with severe aortic valve stenosis (AS) who are inoperable or at high surgical risk, and an attractive alternative in intermediate-risk patients. More recently, randomised trials in low surgical-risk patients showed that TAVI was superior to surgical aortic valve replacement with regard to stroke or death at 1–2 years. Although the incidence of stroke has declined from 2.5%–5% in the early years to 0.6%–3.4% more recently, it remains a concern. Neurocognitive decline can occur after surgical aortic valve replacement, and this has also been documented in patients undergoing TAVI. With TAVI now being performed in younger patients who are expected to be more active and have longer life expectancies, further reducing the stroke risk during TAVI and preserving higher cognitive function after TAVI have become increasingly important. Recently, a novel dual-filter device – the SENTINEL cerebral protection system (CPS) (Boston Scientific, Marlborough, MA, USA) – showed effectiveness in capturing cerebral emboli during TAVI and reducing periprocedural stroke. In this study, we aimed to assess the feasibility, safety, and the clinical and neurocognitive outcomes of TAVI under cerebral protection with the SENTINEL CPS.

METHODS A total of 40 consecutive patients undergoing TAVI owing to symptomatic severe AS in a single centre were included. This was an all-comer study, and patients were enrolled regardless of their surgical risk profile. All patients were reviewed by a cardiologist and a cardiac surgeon and underwent pre-procedure computed tomography (CT) for detailed assessment of the great vessels, particularly tortuosity and size (to determine suitability for the SENTINEL CPS), aortic root (to determine valve type and size) and the peripheral arterial anatomy (to determine suitability for TAVI via femoral access). Carotid ultrasonography scans were

1The Heart and Vascular Centre, Mount Elizabeth Hospital, Yong Loo Lin School of Medicine, National University of Singapore, Charles Chan Heart Clinic, Gleneagles Hospital, 2Heart Matters Medical Centre, Mount Elizabeth Novena Hospital, JTLim Cardiology Clinic, Mount Elizabeth Hospital, The Heart Doctors Clinic, Ascension Heart Centre, Mount Alvernia Hospital, Novena Heart Centre, Mount Elizabeth Novena Hospital, Orchard Heart Specialist Clinic, Mount Elizabeth Hospital, Farrer Park Hospital, Peter Yan Cardiology Clinic, Gleneagles Hospital, Sozo Cardiology, Mount Elizabeth Novena Hospital, The Geriatric Practice, Mount Elizabeth Novena Hospital, Geriatric Education and Research Institute, Ministry of Health, Singapore

Correspondence: Dr Paul Chiam, Cardiologist, The Heart and Vascular Centre, 3 Mount Elizabeth #08-06 Mount Elizabeth Medical Centre, Singapore 228510, paulchiam@heartvascularcentre.com
not performed, as CT provided detailed anatomical assessment to the level of the carotid bifurcation.

All TAVI procedures were performed using the self-expanding Evolut R or Evolut PRO (Medtronic, Dublin, Ireland) prosthesis (Fig. 1), the balloon-expandable SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis (Fig. 2) or the self-expanding Portico (Abbott Vascular, Chicago, IL, USA) prosthesis (Fig. 3). All procedures were performed via transfemoral arterial access under local anaesthesia and conscious sedation. After TAVI, all patients were commenced on dual antiplatelet therapy for six months, and those with pre-existing atrial fibrillation resumed their usual oral anticoagulation regimen.

The filter device was the SENTINEL CPS (Boston Scientific, Marlborough, MA, USA) (Fig. 4), which is currently the only United States Food and Drug Administration (FDA)-approved cerebral protection device for use during TAVI. This device consists of two polyurethane mesh filters with 140-nm pores mounted on a nitinol frame.\[^{13}\] It is introduced via a 6-French sheath in the right radial (or brachial) artery and is advanced over a 0.014-inch coronary angioplasty guide wire. The proximal basket filter is then positioned in the innominate artery and the distal filter is positioned in the left carotid artery (Fig. 5). The filters can accommodate innominate arteries from 9–15 mm and left carotid arteries from 6–10 mm. This has been shown to cover 85%–90% of cerebral blood flow, with the proximal filter protecting the right carotid and right vertebral arteries, and the distal filter protecting the left carotid artery.\[^{14,15}\] The only remaining unprotected area is the brain, supplied by the left vertebral artery. Patients were not suitable for the SENTINEL CPS if there was severe stenosis of the innominate artery or the proximal left carotid artery, and if no right radial or brachial artery access was possible.

Patient characteristics, procedural parameters, and in-hospital, 30-day and nine-month outcomes were recorded. Procedural success (defined as successful transcatheter valve implantation in the correct position without major complications and without moderate or more than moderate paravalvular leak) and all adverse clinical outcomes and events were defined according to the Valve Academic Research Consortium-2 (VARC-2) consensus document.\[^{17}\]

Cognitive assessment, using the abbreviated mental state (AMT)
test, was performed by a healthcare staff who was not involved in this study on all patients before and at 30-day follow-up after TAVI. This questionnaire assesses patients on ten questions, with a score of seven and below indicating neurocognitive impairment. The primary endpoint was either stroke or death at 30 days after TAVI, and the secondary end point was cognitive impairment, as defined by an AMT score of seven or less after TAVI.

Continuous variables were presented as mean ± standard deviation and were compared between groups using a paired t-test. Categorical variables were given as frequencies and percentages and were compared by chi-square test or Fisher’s exact test. A p-value < 0.05 was considered statistically significant. Statistical analyses were performed with IBM SPSS Statistics version 23.0 (IBM Corp, Armonk, NY, USA). All patients provided informed consent for the study.

Table I. Baseline patient characteristics (n = 40).

| Characteristic                              | No. (%)/Mean ± SD |
|--------------------------------------------|-------------------|
| Age (yr)                                   | 76.4 ± 8.4        |
| Male gender                                | 30 (75.0)         |
| Height (cm)                                | 166.0 ± 10.1      |
| Weight (kg)                                | 69.6 ± 13.3       |
| BSA (m²)                                   | 1.78 ± 0.21       |
| BMI (kg/m²)                                | 25.3 ± 3.9        |
| Logistic EuroSCORE*                        | 11.2 ± 9.5        |
| STS PROM score                             | 3.0 ± 2.4         |
| Diabetes mellitus                          | 17 (42.5)         |
| Chronic kidney disease (≥ Stage 3)         | 9 (22.5)          |
| Hypertension                               | 26 (65.0)         |
| Dyslipidaemia                              | 32 (80.0)         |
| Smoker                                     | 2 (5.0)           |
| Prior PCI                                  | 17 (42.5)         |
| Prior CABG                                 | 4 (10.0)          |
| Prior CVA                                  | 3 (7.5)           |
| AF/paroxysmal AF                           | 7 (17.5)          |
| NYHA functional class                      |                   |
| I                                          | 0(0)              |
| II                                         | 13 (32.5)         |
| III                                        | 26 (65.0)         |
| IV                                         | 1 (2.5)           |
| LVEF (%)                                   | 53.0 ± 11.0       |
| AV                                         |                   |
| Area (cm²)                                 | 0.8 ± 0.2         |
| MPG (mmHg)                                 | 51.0 ± 19.0       |
| Moderate/severe AR                         | 5 (12.5)          |
| Moderate/severe MR                         | 4 (10.0)          |
| AV calcium score (HU)                      | 3,759.0 ± 2,271.0 |
| Innominate artery diameter (mm)            | 12.6 ± 1.8        |
| Left carotid artery diameter (mm)          | 7.0 ± 1.2         |

AF: atrial fibrillation; AR: aortic regurgitation; AV: aortic valve; BMI: body mass index; BSA: body surface area; CABG: coronary artery bypass graft; CVA: cerebrovascular accident; LVEF: left ventricular ejection fraction; MPG: mean pressure gradient; MR: mitral regurgitation; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; SD: standard deviation; STS: Society of Thoracic Surgeons; PROM: predicted risk of mortality.

RESULTS

The mean age of our patients was 76.4 ± 8.4 years, and 30 (75.0%) of them were male. The mean left ventricular ejection fraction was 53% ± 11%, and nearly a quarter of patients had chronic kidney disease (≥ Stage 3). Of note, 3 (7.5%) patients had had a previous stroke with good functional recovery. There were two patients with bovine aortic arches and no other arch variants. Various degrees of calcified plaques in the ascending aorta and aortic arch were present in all patients; none, however, had a porcelain aorta, as defined by the VARC-2 consensus document. The baseline characteristics of the patients are summarised in Table I.

All TAVI procedures were successful; the Evolut R or PRO bioprosthesis was used in 20 (50.0%) patients, the SAPIEN 3 bioprosthesis was used in 19 (47.5%) patients and the Portico bioprosthesis was used in the remaining patient. The SENTINEL CPS was successfully deployed in 38 (95.0%) patients (including both patients with bovine aortic arches), with macroscopic debris (Fig. 6) captured by the device in 26 patients. In two patients, severe right subclavian artery and innominate artery tortuosity led to the inability to advance and deploy the SENTINEL CPS.
Table II. Procedural characteristics (n = 40)

| Characteristics                  | No. (%)/Mean ± SD |
|----------------------------------|-------------------|
| SAPIEN 3 valve                   | 19 (47.5)         |
| Evolut R/PRO valve               | 20 (50.0)         |
| Portico valve                    | 1 (2.5)           |
| TAVI procedure success           | 40 (100.0)        |
| Procedure time (min)             | 91.0 ± 19.8       |
| Filter deployment success        | 38.0 (95.0)       |
| Filter-related complications     | 0 (0)             |
| Time to deploy filter (min)      | 7.2 ± 4.7         |

SD: standard deviation; TAVI: transcatheter aortic valve implantation

Table III. Clinical outcomes (n = 40).

| Outcome                              | No. |
|--------------------------------------|-----|
| Death                                | 0   |
| Stroke                               | 0   |
| Myocardial infarction                | 0   |
| Major vascular complications         | 1   |
| Major bleeding                       | 1   |
| Acute kidney injury                  | 0   |
| NYHA class*                          |     |
| I or II                              | 39 (97.5) |
| II to III                            | 1 (2.5)   |
| Permanent pacemaker implantation*    | 1 (2.5) |
| LVEF† (%)                            | 57.0 ± 7.0 |
| AVA† (cm²)                           | 1.8 ± 0.2 |
| AV MPG† (mmHg)                       | 13.0 ± 5.0 |
| Paravalvular leak (moderate/severe)  | 0 (0)  |
| Repeat valve intervention            | 0   |

*Data presented as no. (%); †Data presented as mean ± standard deviation; ‡Due to occult malignancy (n = 1) and pneumonia (n = 1); AV: aortic valve; AVA: aortic valve area; LVEF: left ventricular ejection fraction; MPG: mean pressure gradient; NYHA: New York Heart Association

in the intended location. The mean duration taken to deploy the SENTINEL CPS was 7.2 ± 4.7 minutes. There were no complications from the use of the SENTINEL device (Table II). Of note, there was no radial access site complication.

At 30 days, no stroke or death was observed. All patients reported significant functional status improvement, with almost all patients in New York Heart Association (NYHA) Class I or II. All patients had mild or less than mild paravalvular leak, and 1 (2.5%) patient required a permanent pacemaker implantation. The survival rate at nine months was 95.0% (38 out of 40 patients). One patient suffered from an occult gastric malignancy that was not detected at the time of TAVI and died four months after the procedure. Another patient developed severe sepsis due to pneumonia and died at three months. The clinical and haemodynamic outcomes are shown in Table III.

The cognitive outcomes are shown in Table IV. In the overall cohort, there was no significant change in the mean AMT score before the procedure and at 30 days after the procedure (9.2 ± 1.1 vs. 9.0 ± 1.5, p = 0.12). At baseline, three patients were considered to have impaired cognitive function (AMT score ≤ 7) compared with four patients at the 30-day follow-up (p = 1.0). Most patients (60.0%) had no change in AMT score at baseline and at 30 days, 12.5% of patients had an increase in AMT score and 10% had a decrease in AMT score ≥ 2 at 30 days after TAVI. Compared with patients with preserved or increased AMT scores, those with a decreased score were significantly older (mean age 74.4 ± 7.7 vs. 82.1 ± 4.5, respectively, p = 0.019). All patients with a decrease in AMT score were aged 76 years or older.

DISCUSSION

This study describes the first experience of TAVI with cerebral protection in Southeast Asia, using a novel dual-filter device. The main findings were as follows: the TAVI procedure was successful in all patients, and the SENTINEL CPS was deployed in the intended locations in 95.0% of cases. The time required to deploy the SENTINEL device was under ten minutes, and there were no device-related complications. There was no in-hospital or 30-day stroke or mortality, and survival at nine months was 95.0%. Overall, cognition was preserved, with a similar mean AMT score at baseline and 30 days (9.2 ± 1.1 vs. 9.0 ± 1.5, p = 0.12). Four patients had cognitive impairment at 30 days, compared with three at baseline (p = 1.0). Patients who showed a decrease in AMT score were significantly older, and no patients younger than 76 years experienced a decline in AMT score.

Since TAVI was first performed in Asia and Singapore in 2009, indications have evolved and the case volume has increased throughout Asia. Improvements in valve design and delivery systems have improved clinical outcomes, especially regarding residual paravalvular leak and permanent pacemaker requirements. With TAVI now being performed for lower-surgical-risk and younger patients, stroke risk and neurocognitive preservation have become increasingly important.
Studies using diffusion-weighted MR imaging showed that TAVI resulted in new brain lesions in 68%–84% of cases, and these occurred in both hemispheres and in both anterior and posterior circulations, consistent with cerebral embolisation.\(^{(8,22,23)}\) Although the recent clinical stroke rate is < 3%, more concerning is the fact that silent brain infarcts have been associated with cognitive decline and dementia.\(^{(24)}\)

Various cerebral protection devices have been developed to reduce the embolic burden to the brain during TAVI, with SENTINEL CPS being currently the only device that is FDA approved and has a CE mark. It is designed to capture embolic material – documented to consist of thrombus, calcification, valve tissue, artery wall and foreign material\(^{(11,22,25)}\) – and has been shown to reduce the number and volume of cerebral emboli.\(^{(12,14,16)}\)

While the SENTINEL CPS has been shown to be a safe device, with successful positioning of the filters in 92%–97% of cases, it increases the procedure time by 7–13 minutes and fluoroscopic time by 1.5–3 minutes.\(^{(12,14,16,26)}\) Failures to deploy the SENTINEL CPS were due to significant innominate or right subclavian tortuosity or other complex arch anatomy.\(^{(14,16)}\) This is the major obstacle to SENTINEL CPS positioning, as its design does not allow deployment from a left radial approach. Our experience with the SENTINEL CPS was similar, with no safety issues, a 95% deployment success and an additional time of approximately eight minutes. Importantly, we had only recently started to use the SENTINEL CPS, and with increasing experience, it is likely that the deployment success rate may improve and the additional time required will decrease.

Although the randomised trials of TAVI with the SENTINEL CPS did not show significant stroke reduction because they were underpowered,\(^{(12-14)}\) larger pooled analysis and propensity-matched studies showed a reduction in periprocedural stroke from 4.6%–5.44% to 1.4%–1.88%, with cerebral protection.\(^{(15,16)}\) The SENTINEL CPS would not be expected to completely eliminate 30-day stroke, as it can only prevent or reduce stroke during the immediate periprocedural period (< 24 hours after the procedure) and would not have any effect on the 45% of strokes that are known to occur subsequently.\(^{(16)}\) However, any reduction in stroke burden is highly meaningful, as it adversely affects quality of life and increases mortality threefold.\(^{(10)}\) The aforementioned studies, however, have not shed light on which patients are most likely to benefit from the use of a SENTINEL CPS during TAVI.

In our study, none of the patients developed a stroke. This compares favourably with recent real-world data, where the incidence of 30-day stroke was 2.3% in > 10,000 patients undergoing TAVI without cerebral protection and 1%–2% in patients undergoing TAVI with the SENTINEL CPS.\(^{(15,16,25)}\)

Cognitive decline has been shown to occur in 8%–12% of patients after TAVI,\(^{(15,21,27)}\) with silent cerebral ischaemic lesions being strongly correlated with neurocognitive decline.\(^{(12,21)}\) Cerebral protection with the SENTINEL CPS may reduce cognitive decline, although the current data is conflicting.\(^{(12,13)}\) This may be due to the fact that up to a quarter of these silent cerebral ischaemic lesions were in the vertebrobasilar territory,\(^{(23)}\) and some of these emboli via the left vertebral artery would not be protected with the SENTINEL CPS. In addition, up to 70%–80% of patients have complete resolution of these silent cerebral ischaemic lesions on MR imaging at 3–4 months.\(^{(22,23)}\)

These studies used more extensive neurocognitive tests such as the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE).\(^{(11,23)}\) These tests, however, require trained staff to administer and can be time-consuming. The AMT is much simpler to perform, takes only a few minutes and has been validated against the MoCA and MMS for detecting cognitive impairment.\(^{(15,28)}\) The brevity of the AMT makes it more acceptable to patients and may reduce test error due to language barriers.\(^{(29)}\) An AMT score cut-off of seven and below suggests abnormal cognitive function.\(^{(18,19)}\) However, the AMT was developed mainly as a screening tool for cognitive impairment and was not intended to assess serial cognitive decline.

In this study, preservation of cognitive function was observed, with a similar baseline and 30-day mean AMT score. AMT score decreased by ≥ 2 in 10% of patients, although only 1 (2.5%) additional patient developed impaired cognition at 30 days compared with baseline (4 vs. 3, p = 1.0). A serial decrease in AMT score by ≥ 2 was determined to be significant in some studies\(^{(29,30)}\) despite the lack of validation for AMT score in serial cognitive monitoring. Our results compare positively with a study showing that 25% of patients had a decreased neurocognitive test score, with 8% developing short-term abnormal cognition that persisted in 2% of patients at one year.\(^{(31)}\) Cognitive decline has also been shown to occur in 39%–40% of patients at two months after cardiac surgery, falling to 10%–20% at one year.\(^{(31)}\) Whether there might be similar improvements in our patients with longer follow-up is unknown. However, as we did not have a control arm without the use of the SENTINEL CPS, no firm conclusion on device efficacy in preservation of AMT scores can be drawn.

Conversely, in our study, 12.5% of patients showed an increase in AMT score, which has been hypothesised to be caused by augmented cerebral blood flow as a result of improved cardiac output after relief of the severe AS\(^{(31,27)}\) or simply due to the ‘learning effect’.\(^{(24)}\) This is consistent with previous reports showing that cognitive improvement occurred after TAVI in some patients, more noticeably in those with impaired baseline cognition.\(^{(11,27)}\)

A striking finding in the current study was that patients who exhibited a decline in AMT score were significantly older, with none aged below 76 years. Age has been shown to be independently associated with cognitive decline after TAVI,\(^{(32)}\) likely because older patients tend to have more age-related white matter changes (reduced cerebral reserve),\(^{(15)}\) which increase the risk of silent cerebral ischaemic lesions and cognitive decline after TAVI.\(^{(23)}\) This finding has implications for the counselling of elderly patients under consideration for TAVI; even if stroke risk is negligible, they may be at a higher risk of cognitive decline.

Our study was not without limitations. It was a single-centre feasibility study with a limited number of patients and only an intervention arm; hence, the data should be interpreted with caution. There was no independent neurology assessment, and we cannot exclude the possibility that minor strokes may have been missed, which could have affected the results of this study. The zero-stroke rate could also have been due to the newer-generation TAVI...
devices used, the younger mean age (and lower-risk profile) of our study population and an element of chance owing to the limited sample size. These factors may also have contributed to the good clinical outcomes (e.g. no 30-day mortality, very low permanent pacemaker rate). The neurocognitive assessment was not blinded, and investigator bias could not be excluded. The AMT is also a simple screening tool for the presence of impaired cognition and lacks sensitivity or specificity for the detection of serial cognitive deterioration. There was also no control group without the use of the SENTINEL CPS, and hence, no definite conclusions can be drawn on the efficacy of the device in stroke reduction or cognitive preservation.

In conclusion, we report the initial experience of TAVI with cerebral protection using the SENTINEL CPS in Southeast Asia. The use of Sentinel CPS was safe, with a high rate of successful deployment and required approximately eight minutes of additional procedure time. There was no 30-day stroke or death, and overall cognition was preserved. Only 1 (2.5%) patient developed cognitive impairment at 30 days. Larger studies will be required to further evaluate the role of the SENTINEL CPS during TAVI in Asian patients.

REFERENCES

1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363:1597-607.
2. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic valve-replacement in high-risk patients. N Engl J Med 2011; 364:2187-98.
3. Adams DH, Popma JJ, Reedon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370:1790-8.
4. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic valve-replacement in intermediate-risk patients. N Engl J Med 2016; 374:1609-20.
5. Reedon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic valve-replacement in intermediate-risk patients. N Engl J Med 2017; 376:1321-31.
6. Mack MJ, Leon MB, Thorani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019; 380:1695-705.
7. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019; 380:1706-15.
8. Chiam PT, Ewe SH. An update on complications associated with transcatheter aortic valve implantation: stroke, paravalvular leak, aortoatrial tunnel and perforation. Future Cardiol 2013; 9:733-47.
9. Hudec CP, Tuzcu EM, Krishnaswamy A, et al. Association between transcatheter aortic valve replacement and early postprocedural stroke. JAMA 2019; 321:2306-15.
10. Barber PA, Hach S, Tippett LJ, et al. Cerebral ischemic lesions on diffusion-weighted imaging are associated with neurocognitive decline after cardiac surgery. Stroke 2008; 39:1427-33.
11. Autret V, Campello-Parada F, Regueiro A, et al. Serial changes in cognitive function following transcatheter aortic valve replacement. J Am Coll Cardiol 2016; 68:2129-41.
12. Kapadia SR, Kodali S, Makkar R, et al. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol 2017; 69:367-77.
13. Van Mieghem NM, van Gils L, Ahmad H, et al. Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial. EuroIntervention 2016; 12:499-507.
14. Haussig S, Mannger N, Dwyer MG, et al. Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. JAMA 2016; 316:592-601.
15. Seeger J, Kapadia SR, Kodali S, et al. Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. Eur Heart J 2019; 40:1334-40.
16. Seeger J, Gonska B, Otto M, Rotherauer W, Wöhrle J. Cerebral embolic protection during transcatheter aortic valve replacement significantly reduces death and stroke compared with unprotected procedures. JACC Cardiovasc Interv 2017; 10:2297-303.
17. Kaptein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 2012; 33:2403-18.
18. Jitapunkul S, Pillay I, Ibrahim S. The abbreviated mental test: its use and validity. Age Ageing 1991; 20:312-6.
19. Sahadevan S, Lim PP, Tan NJ, Chan SP. Diagnostic performance of two mental status tests in the older chinese: influence of education and age on cut-off values. Int J Geriatr Psychiatry 2000; 15:234-41.
20. Chiam PT, Koh TH, Chao VT, et al. Percutaneous transcatheter aortic valve replacement: first transfemoral implant in Asia. Singapore Med J 2009; 50:534-7.
21. Chiam PT. Transcatheter aortic valve implantation in Asia: the first decade. EuroIntervention 2018; 14:15-7.
22. Kahlert P, Knipp SC, Schlarmann M, et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation 2010; 121:870-8.
23. De Carlo M, Lija R, Migleluku G, et al. Evolution, predictors, and neurocognitive effects of silent cerebral embolism during transcatheter aortic valve replacement. JACC Cardiovasc Interv 2020; 13:1291-300.
24. Vermmer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348:1215-22.
25. Seeger J, Virmanni R, Romero M, et al. Significant differences in debris captured by the seminal dual-filter cerebral embolic protection during transcatheter aortic valve replacement among different valve types. JACC Cardiovasc Interv 2018; 11:1683-93.
26. Giustino G, Mehran R, Velkkamp R, et al. Neurological outcomes with embolic protection devices in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2016; 9:2124-33.
27. Schoenenberger AW, Zubler C, Moser A, et al. Evolution of cognitive function after transcatheter aortic valve implantation. Circ Cardiovasc Interv 2016; 9:e003590.
28. Pendehurst Y, Klaas SP, Mather M, de Britto M, Wharton RM. Routine cognitive screening in older patients admitted to acute medicine: abbreviated mental test score (AMTS) and subjective memory complaint versus Montreal Cognitive Assessment and IQCODE. Age Ageing 2015; 44:1000-5.
29. Ni Chonchubhair A, Valaciaco R, Kelly J, O’Keefe S. Use of the abbreviated mental test to detect postoperative delirium in elderly people. Br J Anaesth 1995; 75:481-2.
30. Jitapunkul S, Pillay I, Ibrahim S, Delirium in newly admitted elderly patients: a prospective study. Q J Med 1992; 83:307-14.
31. Patel N, Minhas JS, Chung EM. Risk factors associated with cognitive decline after cardiac surgery: a systematic review. Cardiovasc Psychiatry Neurol 2015; 2015:370612.
32. Guhanem A, Kocurek J, Sinning JM, et al. Cognitive trajectory after transcatheter aortic valve implantation. Circ Cardiovasc Interv 2013; 6:801-5.
33. Edlerle J, Danavignam I, van der Worpe HB, et al. Effect of white-matter lesions on the risk of peri-procedural stroke after carotid artery stenting versus endarterectomy in the International Carotid Stenting Study (ICSS): a prespecified analysis of data from a randomised trial. Lancet Neurol 2013; 12:866-72.